Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Little Evidence to Support Most Dietary Interventions for Psoriasis

Marilynn Larkin  |  June 29, 2018

NEW YORK (Reuters Health)—New recommendations from the National Psoriasis Foundation Medical Board suggest that losing weight by following a low-calorie diet can reduce psoriasisseverity in overweight patients, but there is little evidence to support other dietary interventions. “Our psoriasis patients have long asked us about the role of diet on psoriasis,” Dr. April Armstrong of the…

Filed under:Conditions Tagged with:dietary interventionlow-calorie dietNational Psoriasis Foundation Medical Boardpsoriasisseverity

Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 18, 2018

On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…

Filed under:Drug Updates Tagged with:Certolizumab PegolFDAFDA approvalplaque psoriasisPsoriasisU.S. Food and Drug Administration (FDA)

FDA Updates Ixekizumab Label to Include Genital Area Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  June 6, 2018

Ixekizumab is the first agent approved by the FDA for treating plaque psoriasis to include labeling for psoriasis in the genital area…

Filed under:ConditionsDrug Updates Tagged with:FDAgenital psoriasisixekizumabPsoriasisU.S. Food and Drug Administration (FDA)

Guselkumab May Best Adalimumab for Psoriasis on the Scalp, Palms & Soles

Marilynn Larkin  |  May 29, 2018

NEW YORK (Reuters Health)—The interleukin 23 inhibitor guselkumab is associated with more improvement in psoriasis on the scalp, palms and/or soles compared with adalimumab, a new analysis suggests. Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center in Portland conducted a secondary analysis of data from the international VOYAGE 1 and VOYAGE 2 studies, double-blind,…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabfeetguselkumabhandPsoriasisscalp

Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab

Michele B. Kaufman, PharmD, BCGP  |  March 21, 2018

Two Phase 3 clinical trials show that risankizumab is effective for achieving skin clearance in patients with psoriasis…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:brodalumabCanadaplaque psoriasisPsoriasisrisankizumabustekinumab

Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  March 14, 2018

In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…

Filed under:Axial SpondyloarthritisDrug Updates Tagged with:Ankylosing SpondylitisCertolizumab PegolixekizumabPsoriasis

Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 28, 2018

In clinical trials, secukinumab proved safe and effective as a long-term treatment for both palmoplantar and nail psoriasis…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:nail psoriasisnailspalmoplantar psoriasisPsoriasissecukinumab

Psoriasis Tied to Higher Risk of Serious Liver Disease

Lisa Rapaport  |  November 13, 2017

(Reuters Health)—People with chronic inflammatory disorders, such as psoriasis and rheumatoid arthritis (RA), may have an increased risk of developing serious liver damage, a recent study suggests. These inflammatory disorders are often treated with methotrexate, a medication linked to an increased risk of liver disease. For the current study, researchers followed more than 1 million…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:liverliver diseaseMethotrexatePsoriasisRheumatoid Arthritis (RA)skin

Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  November 9, 2017

Medications for serious or life-threatening conditions may receive accelerated approval from the U.S. Food and Drug Administration (FDA) by showing an effect on surrogate measures that are reasonably likely to predict a treatment’s clinical benefit. Post-approval confirmatory drug trials are then required to determine whether or not these effects translate into clinical improvements. In recent…

Filed under:Axial SpondyloarthritisConditionsDrug UpdatesResearch Rheum Tagged with:accelerated approvalAnkylosing SpondylitisClinicaldrugefficacyFDAMedicationoutcomePsoriasisPsoriatic ArthritisResearchrheumatologySafetysecukinumabstudyTreatmenttrial

Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  November 3, 2017

In October, the FDA approved ustekinumab to treat patients 12 years or older who have moderate to severe plaque psoriasis…

Filed under:Drug Updates Tagged with:AdolescentsFDAplaque psoriasisPsoriasisU.S. Food and Drug Administration (FDA)ustekinumab

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences